Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLC-391 in advanced solid tumours
NCT03990454Phase 1Completed
- Sponsor
- SignalChem Lifesciences Corporation
- Start
- Sep 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of slc-391 in solid tumor, sponsored by SignalChem Lifesciences Corporation. Primary endpoints: Number of Participants with Adverse Events (AEs) as assessed by NCI-CTCAE v5.0 at 2 years and Maximum Tolerated Dose of SLC-391 at 21 days. Started Sep 2019; status: completed.
02
Drugs
slc-391
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03990454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990454.